Study shows new obesity treatment semaglutide causes similar weight loss across different age groups

The STEP trials published over the past year have established the efficacy and safety of semaglutide in treating patients with obesity. A new study analysing the effects of this treatment in different age groups presented at this year's European Congress on Obesity (held online, 10-13 May), shows that it has similar effectiveness across different age groups with regard to weight loss (under 40 years, 40-60 years, and 60 years and over).